Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study (Q29620648)
Jump to navigation
Jump to search
scientific article (publication date: August 2011)
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study |
scientific article (publication date: August 2011) |
Statements
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study (English)
2 references
Caicun Zhou
Gongyan Chen
Jifeng Feng
Xiao-Qing Liu
Changli Wang
Shucai Zhang
Jie Wang
Songwen Zhou
Shengxiang Ren
Shun Lu
Li Zhang
Chengping Hu
Chunhong Hu
Yi Luo
Lei Chen
Ming Ye
Jianan Huang
Xiuyi Zhi
Yiping Zhang
Qingyu Xiu
Jun Ma
Li Zhang
2 references
12
2 references
8
2 references
Identifiers
3 references
3 references